Nicholas P Restifo

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9206371/publications.pdf

Version: 2024-02-01

308	74,491	733 124	626 265
papers	citations	h-index	g-index

319	319	319	53641
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Next generation immunotherapy: enhancing stemness of polyclonal T cells to improve anti-tumor activity. Current Opinion in Immunology, 2022, 74, 39-45.	2.4	13
2	Genome-wide Screens Identify Lineage- and Tumor-Specific Genes Modulating MHC-I- and MHC-II-Restricted Immunosurveillance of Human Lymphomas. Immunity, 2021, 54, 116-131.e10.	6.6	72
3	Multiply restimulated human thymic regulatory T cells express distinct signature regulatory T-cell transcription factors without evidence of exhaustion. Cytotherapy, 2021, 23, 704-714.	0.3	7
4	An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature, 2021, 597, 544-548.	13.7	94
5	STING agonist promotes CAR T cell trafficking and persistence in breast cancer. Journal of Experimental Medicine, 2021, 218, .	4.2	84
6	Strength in Numbers: Identifying Neoantigen Targets for Cancer Immunotherapy. Cell, 2020, 183, 591-593.	13.5	18
7	Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. Cancer Cell, 2020, 37, 818-833.e9.	7.7	96
8	Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. , 2020, 8, e000210.		27
9	Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. Clinical Cancer Research, 2020, 26, 1267-1276.	3.2	69
10	Multimodel preclinical platform predicts clinical response of melanoma to immunotherapy. Nature Medicine, 2020, 26, 781-791.	15.2	75
11	Identification of Small Molecule Enhancers of Immunotherapy for Melanoma. Scientific Reports, 2020, 10, 5688.	1.6	7
12	Host conditioning with IL-1Î² improves the antitumor function of adoptively transferred T cells. Journal of Experimental Medicine, 2019, 216, 2619-2634.	4.2	51
13	The Bone Marrow Protects and Optimizes Immunological Memory during Dietary Restriction. Cell, 2019, 178, 1088-1101.e15.	13.5	160
14	Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of miceÂbearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer Immunology, Immunotherapy, 2019, 68, 1805-1817.	2.0	40
15	Using Human Induced Pluripotent Stem Cells for the Generation of Tumor Antigen-specific T Cells. Journal of Visualized Experiments, 2019, , .	0.2	4
16	A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants. Journal of Visualized Experiments, 2019, , .	0.2	3
17	Defining â€˜T cell exhaustionâ€™. Nature Reviews Immunology, 2019, 19, 665-674.	10.6	879
18	Ribosomal Proteins Regulate MHC Class I Peptide Generation for Immunosurveillance. Molecular Cell, 2019, 73, 1162-1173.e5.	4.5	81

#	Article	IF	Citations
19	Mg2+ regulation of kinase signaling and immune function. Journal of Experimental Medicine, 2019, 216, 1828-1842.	4.2	37
20	T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science, 2019, 363, .	6.0	355
21	The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity. Nature Immunology, 2019, 20, 337-349.	7.0	113
22	Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptorâ€“transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. Journal of Immunotherapy, 2019, 42, 126-135.	1.2	231
23	Developing neoantigen-targeted T cellâ€“based treatments for solid tumors. Nature Medicine, 2019, 25, 1488-1499.	15.2	173
24	Identifying the source of tumour-infiltrating T cells. Nature, 2019, 576, 385-386.	13.7	5
25	An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. JCI Insight, 2019, 4, .	2.3	36
26	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. Journal of Clinical Investigation, 2019, 129, 1551-1565.	3.9	108
27	Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. Journal of Clinical Investigation, 2019, 129, 1109-1114.	3.9	193
28	The Cish SH2 domain is essential for PLC-Î³1 regulation in TCR stimulated CD8+ T cells. Scientific Reports, 2018, 8, 5336.	1.6	32
29	Epigenetic control of CD8+ T cell differentiation. Nature Reviews Immunology, 2018, 18, 340-356.	10.6	334
30	A cleavage product of Polycystin-1 is a mitochondrial matrix protein that affects mitochondria morphology and function when heterologously expressed. Scientific Reports, 2018, 8, 2743.	1.6	75
31	Silencing stemness in T cell differentiation. Science, 2018, 359, 163-164.	6.0	18
32	Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. Cell Reports, 2018, 22, 3175-3190.	2.9	35
33	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight, 2018, 3, .	2.3	110
34	Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism. Cell, 2018, 175, 1780-1795.e19.	13.5	445
35	Metabolic reprograming of anti-tumor immunity. Current Opinion in Immunology, 2017, 46, 14-22.	2.4	85
36	Novel â€œElementsâ€•of Immune Suppression within the Tumor Microenvironment. Cancer Immunology Research, 2017, 5, 426-433.	1.6	52

#	Article	IF	Citations
37	BACH2 immunodeficiency illustrates an association between super-enhancers and haploinsufficiency. Nature Immunology, 2017, 18, 813-823.	7.0	113
38	Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Clinical Cancer Research, 2017, 23, 2478-2490.	3.2	95
39	ASXL3 Is a Novel Pluripotency Factor in Human Respiratory Epithelial Cells and a Potential Therapeutic Target in Small Cell Lung Cancer. Cancer Research, 2017, 77, 6267-6281.	0.4	20
40	Identification of essential genes for cancer immunotherapy. Nature, 2017, 548, 537-542.	13.7	668
41	Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. Cell Metabolism, 2017, 26, 94-109.	7.2	374
42	Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clinical Cancer Research, 2017, 23, 2267-2276.	3.2	64
43	Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight, 2017, 2, .	2.3	142
44	Fas/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction. Nature Communications, 2016, 7, 13895.	5.8	45
45	Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. Journal of Clinical Oncology, 2016, 34, 2389-2397.	0.8	293
46	BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers. Nature Immunology, 2016, 17, 851-860.	7.0	221
47	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. Cellular and Molecular Immunology, 2016, 13, 502-513.	4.8	99
48	Customizing Functionality and Payload Delivery for Receptor-Engineered T Cells. Cell, 2016, 167, 304-306.	13.5	5
49	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. Cell, 2016, 166, 1117-1131.e14.	13.5	203
50	Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature, 2016, 537, 539-543.	13.7	479
51	Arginine Arms T Cells to Thrive and Survive. Cell Metabolism, 2016, 24, 647-648.	7.2	22
52	Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. Journal of Immunology, 2016, 197, 644-654.	0.4	18
53	Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning. , 2016, 4, 6.		23
54	Acquired resistance to immunotherapy and future challenges. Nature Reviews Cancer, 2016, 16, 121-126.	12.8	353

#	Article	IF	Citations
55	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metabolism, 2016, 23, 63-76.	7.2	291
56	Targeting Akt in cell transfer immunotherapy for cancer. OncoImmunology, 2016, 5, e1014776.	2.1	6
57	Prospects for gene-engineered T cell immunotherapy for solid cancers. Nature Medicine, 2016, 22, 26-36.	15.2	296
58	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunology Research, 2016, 4, 204-214.	1.6	175
59	The transcription factor BACH2 promotes tumor immunosuppression. Journal of Clinical Investigation, 2016, 126, 599-604.	3.9	49
60	Inhibition of the T cell oxygen sensing machinery promotes anti-tumor efficacy. , 2015, 3, .		0
61	The kinase DYRK1A reciprocally regulates the differentiation of Th17 and regulatory T cells. ELife, 2015, 4, .	2.8	48
62	Consensus nomenclature for CD8⁺T cell phenotypes in cancer. OncoImmunology, 2015, 4, e998538.	2.1	119
63	Tumor-Infiltrating Lymphocytes Genetically Engineered with an Inducible Gene Encoding Interleukin-12 for the Immunotherapy of Metastatic Melanoma. Clinical Cancer Research, 2015, 21, 2278-2288.	3.2	310
64	miR-155 augments CD8 ⁺ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic Î³ _c cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 476-481.	3.3	99
65	Mouse Model for Preâ€Clinical Study of Human Cancer Immunotherapy. Current Protocols in Immunology, 2015, 108, 20.1.1-20.1.43.	3.6	23
66	Microbiota Modulation of Myeloid Cells in Cancer Therapy. Cancer Immunology Research, 2015, 3, 103-109.	1.6	31
67	Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature, 2015, 520, 558-562.	13.7	323
68	Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. Cancer Research, 2015, 75, 296-305.	0.4	283
69	A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1â€“Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response. Clinical Cancer Research, 2015, 21, 1019-1027.	3.2	677
70	Adoptive cell transfer as personalized immunotherapy for human cancer. Science, 2015, 348, 62-68.	6.0	1,911
71	The interplay of effector and regulatory T cells in cancer. Current Opinion in Immunology, 2015, 33, 101-111.	2.4	114
72	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy, 2015, 23, 1380-1390.	3.7	88

#	Article	IF	Citations
73	Complete Regression of Metastatic Cervical Cancer After Treatment With Human Papillomavirusâ€“Targeted Tumor-Infiltrating T Cells. Journal of Clinical Oncology, 2015, 33, 1543-1550.	0.8	513
74	Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. Journal of Experimental Medicine, 2015, 212, 2095-2113.	4.2	147
75	Nutrient Competition: A New Axis of Tumor Immunosuppression. Cell, 2015, 162, 1206-1208.	13.5	102
76	Transcriptional profiles reveal a stepwise developmental program of memory CD8+ T cell differentiation. Vaccine, 2015, 33, 914-923.	1.7	29
77	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. Cancer Immunology Research, 2015, 3, 37-47.	1.6	24
78	Memory T cellâ€“driven differentiation of naive cells impairs adoptive immunotherapy. Journal of Clinical Investigation, 2015, 126, 318-334.	3.9	193
79	Identification of the Genomic Insertion Site of Pmel-1 TCR Î± and Î² Transgenes by Next-Generation Sequencing. PLoS ONE, 2014, 9, e96650.	1.1	24
80	Classification of current anticancer immunotherapies. Oncotarget, 2014, 5, 12472-12508.	0.8	395
81	Stem cells and cancer immunotherapy: Arrowheadâ€™s 2nd annual cancer immunotherapy conference. , 2014, 2, .		1
82	Reprogramming antitumor immunity. Trends in Immunology, 2014, 35, 178-185.	2.9	39
83	Human memory T cells: generation, compartmentalization and homeostasis. Nature Reviews Immunology, 2014, 14, 24-35.	10.6	699
84	Treatment of aggressive lymphomas with anti-CD19 CAR T cells. Nature Reviews Clinical Oncology, 2014, 11, 685-686.	12.5	11
85	Uncoupling Tâ€cell expansion from effector differentiation in cellâ€based immunotherapy. Immunological Reviews, 2014, 257, 264-276.	2.8	102
86	Tumorâ€specific <scp>CD</scp>4⁺<scp>T</scp> cells maintain effector and memory tumorâ€specific <scp>CD</scp>8⁺<scp>T</scp> cells. European Journal of Immunology, 2014, 44, 69-79.	1.6	98
87	A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer. Human Gene Therapy, 2014, 25, 1003-1012.	1.4	152
88	Engineering the immune response to "self" for effective cancer immunotherapy. , 2014, 2, P22.		0
89	Big bang theory of stem-like T cells confirmed. Blood, 2014, 124, 476-477.	0.6	15
90	HPV-targeted tumor-infiltrating lymphocytes for cervical cancer.. Journal of Clinical Oncology, 2014, 32, LBA3008-LBA3008.	0.8	6

#	Article	IF	Citations
91	Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. , 2013, 1, 11.		56
92	Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting. , 2013, 1, .		5
93	Double or nothing on cancer immunotherapy. Nature Biotechnology, 2013, 31, 33-34.	9.4	21
94	Lineage relationship of effector and memory T cells. Current Opinion in Immunology, 2013, 25, 556-563.	2.4	173
95	A â€œBig Dataâ€•View of the Tumor â€œImmunomeâ€• Immunity, 2013, 39, 631-632.	6.6	17
96	Reassessing target antigens for adoptive T-cell therapy. Nature Biotechnology, 2013, 31, 999-1008.	9.4	181
97	Essentials of Th17 cell commitment and plasticity. Blood, 2013, 121, 2402-2414.	0.6	306
98	Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunology, Immunotherapy, 2013, 62, 727-736.	2.0	80
99	Memoirs of a Reincarnated T Cell. Cell Stem Cell, 2013, 12, 6-8.	5.2	11
100	Randomized Selection Design Trial Evaluating CD8⁺-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma. Journal of Clinical Oncology, 2013, 31, 2152-2159.	0.8	196
101	Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas. Molecular Therapy, 2013, 21, 1369-1377.	3.7	62
102	MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer. Immunity, 2013, 38, 742-753.	6.6	278
103	BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis. Nature, 2013, 498, 506-510.	13.7	332
104	Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nature Protocols, 2013, 8, 33-42.	5.5	181
105	Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice. Cancer Research, 2013, 73, 3371-3380.	0.4	89
106	Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy. Journal of Immunotherapy, 2013, 36, 133-151.	1.2	953
107	T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6973-6978.	3.3	203
108	Retinoic acid controls the homeostasis of pre-cDCâ€“derived splenic and intestinal dendritic cells. Journal of Experimental Medicine, 2013, 210, 1961-1976.	4.2	120

#	Article	IF	Citations
109	Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. Journal of Experimental Medicine, 2013, 210, 1125-1135.	4.2	321
110	Moving T memory stem cells to the clinic. Blood, 2013, 121, 567-568.	0.6	59
111	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. Journal of Clinical Investigation, 2013, 123, 4479-4488.	3.9	719
112	Superior T memory stem cell persistence supports long-lived T cell memory. Journal of Clinical Investigation, 2013, 123, 594-9.	3.9	287
113	Nine lives for TH9s?. Nature Medicine, 2012, 18, 1177-1178.	15.2	2
114	141â€ƒThe Role of T Memory Stem Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 59.	0.9	1
115	Sorting Through Subsets. Journal of Immunotherapy, 2012, 35, 651-660.	1.2	237
116	The power and pitfalls of IL-12. Blood, 2012, 119, 4096-4097.	0.6	15
117	The Stoichiometric Production of IL-2 and IFN-Î³ mRNA Defines Memory T Cells That Can Self-Renew After Adoptive Transfer in Humans. Science Translational Medicine, 2012, 4, 149ra120.	5.8	51
118	Increased Frequency of Suppressive Regulatory T Cells and T Cell-Mediated Antigen Loss Results in Murine Melanoma Recurrence. Journal of Immunology, 2012, 189, 767-776.	0.4	28
119	Paths to stemness: building the ultimate antitumour T cell. Nature Reviews Cancer, 2012, 12, 671-684.	12.8	487
120	Local Delivery of Interleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice. Clinical Cancer Research, 2012, 18, 1672-1683.	3.2	244
121	Cellular Constituents of Immune Escape within the Tumor Microenvironment. Cancer Research, 2012, 72, 3125-3130.	0.4	308
122	Adoptive immunotherapy for cancer: harnessing the T cell response. Nature Reviews Immunology, 2012, 12, 269-281.	10.6	1,412
123	Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nature Immunology, 2011, 12, 1230-1237.	7.0	165
124	Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Research, 2011, 21, 1650-1658.	2.4	160
125	A human memory T cell subset with stem cellâ€“like properties. Nature Medicine, 2011, 17, 1290-1297.	15.2	1,547
126	Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature. Immunity, 2011, 35, 972-985.	6.6	392

#	Article	IF	Citations
127	Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies. Journal of Immunotherapy, 2011, 34, 343-352.	1.2	80
128	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood, 2011, 117, 808-814.	0.6	272
129	Therapeutic cancer vaccines: are we there yet?. Immunological Reviews, 2011, 239, 27-44.	2.8	249
130	Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer, 2011, 11, 451.	1.1	20
131	Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy. Clinical Cancer Research, 2011, 17, 4550-4557.	3.2	1,823
132	InÂvitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking inÂvivo antigen-experienced cells. Cancer Immunology, Immunotherapy, 2011, 60, 739-749.	2.0	44
133	Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunology, Immunotherapy, 2011, 60, 671-683.	2.0	74
134	Improving Adoptive T Cell Therapy by Targeting and Controlling IL-12 Expression to the Tumor Environment. Molecular Therapy, 2011, 19, 751-759.	3.7	233
135	Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. Clinical Cancer Research, 2011, 17, 5343-5352.	3.2	247
136	Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1. Journal of Clinical Oncology, 2011, 29, 917-924.	0.8	1,427
137	A TCR Targeting the HLA-A*0201â€“Restricted Epitope of MAGE-A3 Recognizes Multiple Epitopes of the MAGE-A Antigen Superfamily in Several Types of Cancer. Journal of Immunology, 2011, 186, 685-696.	0.4	150
138	Polymeric Structure and Host Toll-like Receptor 4 Dictate Immunogenicity of NY-ESO-1 Antigen in Vivo. Journal of Biological Chemistry, 2011, 286, 37077-37084.	1.6	7
139	T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis. Molecular Therapy, 2011, 19, 620-626.	3.7	857
140	IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. Journal of Clinical Investigation, 2011, 121, 4746-4757.	3.9	283
141	Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells. Journal of Immunotherapy, 2010, 33, 1-7.	1.2	236
142	Different Adjuvanticity of Incomplete Freund's Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine. Journal of Immunotherapy, 2010, 33, 626-629.	1.2	24
143	Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, 2010, 116, 3875-3886.	0.6	301
144	Can Antitumor Immunity Help to Explain â€œOncogene Addictionâ€?. Cancer Cell, 2010, 18, 403-405.	7.7	19

#	Article	IF	Citations
145	IFNâ€Î³â€receptor signaling ameliorates transplant vasculopathy through attenuation of CD8⁺ Tâ€cellâ€mediated injury of vascular endothelial cells. European Journal of Immunology, 2010, 40, 733-743.	1.6	18
146	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nature Medicine, 2010, 16, 339-345.	15.2	122
147	Reply to: â€œÎ²-catenin does not regulate memory T cell phenotypeâ€. Nature Medicine, 2010, 16, 514-515.	15.2	18
148	TH17 cells in tumour immunity and immunotherapy. Nature Reviews Immunology, 2010, 10, 248-256.	10.6	531
149	Both CD4 and CD8 T Cells Mediate Equally Effective In Vivo Tumor Treatment When Engineered with a Highly Avid TCR Targeting Tyrosinase. Journal of Immunology, 2010, 184, 5988-5998.	0.4	75
150	Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer. Cancer Research, 2010, 70, 6171-6180.	0.4	573
151	Naive tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma. Journal of Experimental Medicine, 2010, 207, 651-667.	4.2	389
152	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. Journal of Experimental Medicine, 2010, 207, 637-650.	4.2	715
153	Wnt/Î²-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy. Clinical Cancer Research, 2010, 16, 4695-4701.	3.2	145
154	CD8+ Enriched â€œYoungâ€•Tumor Infiltrating Lymphocytes Can Mediate Regression of Metastatic Melanoma. Clinical Cancer Research, 2010, 16, 6122-6131.	3.2	269
155	GILT Accelerates Autoimmunity to the Melanoma Antigen Tyrosinase-Related Protein 1. Journal of Immunology, 2010, 185, 2828-2835.	0.4	47
156	Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts. Cancer Research, 2010, 70, 6725-6734.	0.4	227
157	Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity. Journal of Clinical Investigation, 2010, 120, 4273-4288.	3.9	19
158	Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. Journal of Clinical Investigation, 2010, 120, 3953-3968.	3.9	199
159	Adoptively transferred effector cells derived from naÃ¯ve rather than central memory CD8 ⁺ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17469-17474.	3.3	348
160	Viral Sequestration of Antigen Subverts Cross Presentation to CD8+ T Cells. PLoS Pathogens, 2009, 5, e1000457.	2.1	35
161	Pharmacologic Induction of CD8 ⁺ T Cell Memory: Better Living Through Chemistry. Science Translational Medicine, 2009, 1, 11ps12.	5.8	61
162	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Medicine, 2009, 15, 808-813.	15.2	839

#	Article	IF	Citations
163	Adoptive immunotherapy of cancer using CD4+ T cells. Current Opinion in Immunology, 2009, 21, 200-208.	2.4	202
164	Adoptive T cell therapy of cancer. Current Opinion in Immunology, 2009, 21, 187-189.	2.4	22
165	T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity. Immunity, 2009, 31, 787-798.	6.6	679
166	Ocular and Systemic Autoimmunity after Successful Tumor-Infiltrating Lymphocyte Immunotherapy for Recurrent, Metastatic Melanoma. Ophthalmology, 2009, 116, 981-989.e1.	2.5	88
167	Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends in Immunology, 2009, 30, 592-602.	2.9	229
168	High-avidity Autoreactive CD4+ T Cells Induce Host CTL, Overcome Tregs and Mediate Tumor Destruction. Journal of Immunotherapy, 2009, 32, 677-688.	1.2	18
169	Type 17 CD8+ T cells display enhanced antitumor immunity. Blood, 2009, 114, 596-599.	0.6	196
170	Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood, 2009, 114, 1776-1783.	0.6	26
171	Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood, 2009, 114, 535-546.	0.6	1,280
172	Does IL-17 promote tumor growth?. Blood, 2009, 114, 231-232.	0.6	26
173	Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews Cancer, 2008, 8, 299-308.	12.8	1,404
174	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood, 2008, 112, 4746-4754.	0.6	39
175	IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood, 2008, 111, 5326-5333.	0.6	380
176	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8061-8066.	3.3	114
177	Cancer Immunotherapy. New England Journal of Medicine, 2008, 359, 1072-1073.	13.9	45
178	TSCOT + Thymic Epithelial Cell-Mediated Sensitive CD4 Tolerance by Direct Presentation. PLoS Biology, 2008, 6, e191.	2.6	16
179	Treatment of Metastatic Melanoma Using Interleukin-2 Alone or in Conjunction with Vaccines. Clinical Cancer Research, 2008, 14, 5610-5618.	3.2	207
180	Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens. Journal of Clinical Oncology, 2008, 26, 5233-5239.	0.8	1,210

#	Article	IF	Citations
181	Immunologic ignorance of vascular endothelial cells expressing minor histocompatibility antigen. Blood, 2008, 111, 4588-4595.	0.6	13
182	Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, 2008, 112, 362-373.	0.6	719
183	T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. Journal of Immunotherapy, 2008, 31, 1-6.	1.2	63
184	IL12 polarization of mouse and human Tâ€cells: implications for adoptive immunotherapy. FASEB Journal, 2008, 22, .	0.2	0
185	Extrathymic Generation of Tumor-Specific T Cells from Genetically Engineered Human Hematopoietic Stem Cells via Notch Signaling. Cancer Research, 2007, 67, 2425-2429.	0.4	87
186	5-AZA-2â€²-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story. Cancer Research, 2007, 67, 2901-2901.	0.4	0
187	Toll-like Receptors in Tumor Immunotherapy. Clinical Cancer Research, 2007, 13, 5280-5289.	3.2	114
188	Structures of MART-126/27â€“35 Peptide/HLA-A2 Complexes Reveal a Remarkable Disconnect between Antigen Structural Homology and T Cell Recognition. Journal of Molecular Biology, 2007, 372, 1123-1136.	2.0	90
189	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation, 2007, 117, 2197-2204.	3.9	456
190	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation, 2007, 117, 3140-3140.	3.9	2
191	Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. Journal of Clinical Investigation, 2007, 117, 492-501.	3.9	181
192	Increased intensity lymphodepletion and adoptive immunotherapyâ€”how far can we go?. Nature Clinical Practice Oncology, 2006, 3, 668-681.	4.3	318
193	Interleukin-2-Dependent Mechanisms of Tolerance and Immunity In Vivo. Journal of Immunology, 2006, 176, 5255-5266.	0.4	109
194	Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes. Science, 2006, 314, 126-129.	6.0	2,352
195	Type I Interferons are essential for the efficacy of replicase-based DNA vaccines. Vaccine, 2006, 24, 5110-5118.	1.7	48
196	CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood, 2006, 108, 3818-3823.	0.6	59
197	Altered CD8+ T-Cell Responses When Immunizing With Multiepitope Peptide Vaccines. Journal of Immunotherapy, 2006, 29, 224-231.	1.2	31
198	CD8 + Tâ€cell memory in tumor immunology and immunotherapy. Immunological Reviews, 2006, 211, 214-224.	2.8	434

#	Article	IF	Citations
199	Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology, 2006, 119, 63-73.	2.0	30
200	Adoptive immunotherapy for cancer: building on success. Nature Reviews Immunology, 2006, 6, 383-393.	10.6	801
201	Programming CD8+ T cells for effective immunotherapy. Current Opinion in Immunology, 2006, 18, 363-370.	2.4	61
202	Sensitization of B16 tumor cells with a CXCR4 antagonist increases the efficacy of immunotherapy for established lung metastases. Molecular Cancer Therapeutics, 2006, 5, 2592-2599.	1.9	49
203	De novo Induction of a Cancer/Testis Antigen by 5-Aza-2â€²-Deoxycytidine Augments Adoptive Immunotherapy in a Murine Tumor Model. Cancer Research, 2006, 66, 1105-1113.	0.4	133
204	The In vivo Expansion Rate of Properly Stimulated Transferred CD8+ T Cells Exceeds That of an Aggressively Growing Mouse Tumor. Cancer Research, 2006, 66, 1132-1138.	0.4	49
205	Evaluation of Prime/Boost Regimens Using Recombinant Poxvirus/Tyrosinase Vaccines for the Treatment of Patients with Metastatic Melanoma. Clinical Cancer Research, 2006, 12, 2526-2537.	3.2	50
206	Immunological and Antitumor Effects of IL-23 as a Cancer Vaccine Adjuvant. Journal of Immunology, 2006, 176, 5213-5222.	0.4	81
207	Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity. Cancer Research, 2006, 66, 4904-4912.	0.4	195
208	High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Molecular Therapy, 2006, 13, 151-159.	3.7	260
209	Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.. Blood, 2006, 108, 5210-5210.	0.6	0
210	Treatment of Established B16 Murine Melanoma Tumors with Tyrp-1 Specific CD4+ Lymphocytes.. Blood, 2006, 108, 3688-3688.	0.6	0
211	Glucocorticoids Do Not Inhibit Antitumor Activity of Activated CD8+ T Cells. Journal of Immunotherapy, 2005, 28, 517-524.	1.2	57
212	CD4+CD25+ T Regulatory Cells, Immunotherapy of Cancer, and Interleukin-2. Journal of Immunotherapy, 2005, 28, 120-128.	1.2	199
213	Less is more: lymphodepletion followed by hematopoietic stem cell transplant augments adoptive T-cell-based anti-tumor immunotherapy. Current Opinion in Immunology, 2005, 17, 195-201.	2.4	101
214	Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Antiâ€“Cytotoxic T-Lymphocyte Antigen-4. Journal of Clinical Oncology, 2005, 23, 6043-6053.	0.8	989
215	Bcl-2 Overexpression Enhances Tumor-Specific T-Cell Survival. Cancer Research, 2005, 65, 2001-2008.	0.4	122
216	Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. Journal of Experimental Medicine, 2005, 201, 139-148.	4.2	636

#	Article	IF	Citations
217	Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. Journal of Clinical Investigation, 2005, 115, 1616-1626.	3.9	815
218	Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. Journal of Experimental Medicine, 2005, 202, 907-912.	4.2	951
219	Immune Selection of Hot-Spot Î²2-Microglobulin Gene Mutations, HLA-A2 Allospecificity Loss, and Antigen-Processing Machinery Component Down-Regulation in Melanoma Cells Derived from Recurrent Metastases following Immunotherapy. Journal of Immunology, 2005, 174, 1462-1471.	0.4	96
220	Increased Immunogenicity of an Anchor-Modified Tumor-Associated Antigen Is Due to the Enhanced Stability of the Peptide/MHC Complex: Implications for Vaccine Design. Journal of Immunology, 2005, 174, 4812-4820.	0.4	99
221	Tumor Progression Can Occur despite the Induction of Very High Levels of Self/Tumor Antigen-Specific CD8+ T Cells in Patients with Melanoma. Journal of Immunology, 2005, 175, 6169-6176.	0.4	428
222	CD8+ T Cell Immunity Against a Tumor/Self-Antigen Is Augmented by CD4+ T Helper Cells and Hindered by Naturally Occurring T Regulatory Cells. Journal of Immunology, 2005, 174, 2591-2601.	0.4	662
223	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9571-9576.	3.3	810
224	Adoptive Cell Transfer Therapy Following Non-Myeloablative but Lymphodepleting Chemotherapy for the Treatment of Patients With Refractory Metastatic Melanoma. Journal of Clinical Oncology, 2005, 23, 2346-2357.	0.8	1,452
225	Interleukin-7-Dependent Expansion and Persistence of Melanoma-Specific T Cells in Lymphodepleted Mice Lead to Tumor Regression and Editing. Cancer Research, 2005, 65, 10569-10577.	0.4	81
226	Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends in Immunology, 2005, 26, 111-117.	2.9	410
227	Use of standard criteria for assessment of cancer vaccines. Lancet Oncology, The, 2005, 6, 3-4.	5.1	14
228	Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo. Cancer Research, 2004, 64, 6783-6790.	0.4	116
229	IL-15 enhances thein vivoantitumor activity of tumor-reactive CD8+T Cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1969-1974.	3.3	499
230	Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction. Journal of Immunology, 2004, 173, 7209-7216.	0.4	110
231	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology, 2004, 76, 333-337.	1.5	43
232	Cancer immunotherapy: moving beyond current vaccines. Nature Medicine, 2004, 10, 909-915.	15.2	2,708
233	Reply to "Cancer vaccines: pessimism in check". Nature Medicine, 2004, 10, 1279-1280.	15.2	19
234	Apoptosis is essential for the increased efficacy of alphaviral replicase-based DNA vaccines. Vaccine, 2004, 22, 1537-1544.	1.7	67

#	Article	IF	Citations
235	Poor immunogenicity of a self/tumor antigen derives from peptideâ€“MHC-I instability and is independent of tolerance. Journal of Clinical Investigation, 2004, 114, 551-559.	3.9	104
236	Poor immunogenicity of a self/tumor antigen derives from peptideâ€“MHC-I instability and is independent of tolerance. Journal of Clinical Investigation, 2004, 114, 551-559.	3.9	66
237	Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways. Nature Medicine, 2003, 9, 33-39.	15.2	260
238	Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10. Journal of Experimental Medicine, 2003, 198, 1337-1347.	4.2	148
239	Normal Tissue Depresses While Tumor Tissue Enhances Human T Cell Responses In Vivo to a Novel Self/Tumor Melanoma Antigen, OA1. Journal of Immunology, 2003, 170, 1579-1585.	0.4	26
240	Inability to Immunize Patients with Metastatic Melanoma Using Plasmid DNA Encoding the gp100 Melanoma-Melanocyte Antigen. Human Gene Therapy, 2003, 14, 709-714.	1.4	105
241	Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8372-8377.	3.3	1,482
242	Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells. Journal of Experimental Medicine, 2003, 198, 569-580.	4.2	865
243	High Efficiency TCR Gene Transfer into Primary Human Lymphocytes Affords Avid Recognition of Melanoma Tumor Antigen Glycoprotein 100 and Does Not Alter the Recognition of Autologous Melanoma Antigens. Journal of Immunology, 2003, 171, 3287-3295.	0.4	219
244	Immunization of Patients with Metastatic Melanoma Using Both Class I- and Class II-Restricted Peptides from Melanoma-Associated Antigens. Journal of Immunotherapy, 2003, 26, 349-356.	1.2	118
245	Cell Transfer Therapy for Cancer: Lessons from Sequential Treatments of a Patient With Metastatic Melanoma. Journal of Immunotherapy, 2003, 26, 385-393.	1.2	58
246	DNA vaccines and apoptosis: to kill or not to kill?. Journal of Clinical Investigation, 2003, 112, 22-24.	3.9	20
247	DNA vaccines and apoptosis: to kill or not to kill?. Journal of Clinical Investigation, 2003, 112, 22-24.	3.9	10
248	Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clinical Cancer Research, 2003, 9, 2973-80.	3.2	82
249	Intensity of the Vaccine-Elicited Immune Response Determines Tumor Clearance. Journal of Immunology, 2002, 168, 338-347.	0.4	83
250	Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes. Science, 2002, 298, 850-854.	6.0	2,598
251	Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC. Prostate, 2002, 53, 183-191.	1.2	10
252	MHC class I and class II presentation of tumor antigen in retrovirally and adenovirally transduced dendritic cells. Cancer Gene Therapy, 2002, 9, 946-950.	2.2	25

#	Article	IF	Citations
253	Natural selection of tumor variants in the generation of â€œtumor escapeâ€•phenotypes. Nature Immunology, 2002, 3, 999-1005.	7.0	911
254	Assumptions of the tumor â€˜escapeâ€™ hypothesis. Seminars in Cancer Biology, 2002, 12, 81-86.	4.3	26
255	Do CD4+CD25+ Immunoregulatory T Cells Hinder Tumor Immunotherapy?. Journal of Immunotherapy, 2002, 25, 202-206.	1.2	67
256	Cancer vaccines: progress reveals new complexities. Journal of Clinical Investigation, 2002, 110, 289-294.	3.9	65
257	Induction of CD4+ T cellâ€“dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. Journal of Clinical Investigation, 2002, 109, 1463-1470.	3.9	25
258	Induction of CD4+ T cellâ€“dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. Journal of Clinical Investigation, 2002, 109, 1463-1470.	3.9	77
259	Cancer vaccines: progress reveals new complexities. Journal of Clinical Investigation, 2002, 110, 289-294.	3.9	40
260	Expression of a "self-"antigen by human tumor cells enhances tumor antigen-specific CD4(+) T-cell function. Cancer Research, 2002, 62, 5144-7.	0.4	24
261	Elucidating the Autoimmune and Antitumor Effector Mechanisms of a Treatment Based on Cytotoxic T Lymphocyte Antigen-4 Blockade in Combination with a B16 Melanoma Vaccine. Journal of Experimental Medicine, 2001, 194, 481-490.	4.2	307
262	Creating therapeutic cancer vaccines: notes from the battlefield. Trends in Immunology, 2001, 22, 5-7.	2.9	23
263	Countering the 'counterattack' hypothesis. Nature Medicine, 2001, 7, 259-259.	15.2	63
264	Vaccines to die for. Nature Biotechnology, 2001, 19, 527-528.	9.4	20
265	Hierarchy, Tolerance, and Dominance in the Antitumor T-Cell Response. Journal of Immunotherapy, 2001, 24, 193-194.	1.2	8
266	Building better vaccines: how apoptotic cell death can induce inflammation and activate innate and adaptive immunity. Current Opinion in Immunology, 2000, 12, 597-603.	2.4	138
267	Not so Fas: Re-evaluating the mechanisms of immune privilege and tumor escape. Nature Medicine, 2000, 6, 493-495.	15.2	238
268	Antitumor efficacy of tumor-antigen-encoding recombinant poxvirus immunization in Dunning rat prostate cancer: implications for clinical genetic vaccine development. World Journal of Urology, 2000, 18, 136-142.	1.2	8
269	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood, 2000, 96, 3838-3846.	0.6	474
270	Poxviruses as vectors for cancer immunotherapy. , 2000, , 47-61.		5

#	Article	IF	Citations
271	Self-Tolerance to the Murine Homologue of a Tyrosinase-Derived Melanoma Antigen. Journal of Experimental Medicine, 2000, 191, 1221-1232.	4.2	154
272	Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice. Journal of Immunology, 2000, 164, 3535-3542.	0.4	124
273	Dose-Dependent and Schedule-Dependent Effects of Interleukin-12 on Antigen-Specific CD8 Responses. Journal of Interferon and Cytokine Research, 2000, 20, 589-596.	0.5	10
274	Cutting Edge: CD4+T Cell Control of CD8+T Cell Reactivity to a Model Tumor Antigen. Journal of Immunology, 2000, 164, 562-565.	0.4	161
275	Identification of CD4+ T Cell Epitopes from NY-ESO-1 Presented by HLA-DR Molecules. Journal of Immunology, 2000, 165, 1153-1159.	0.4	130
276	B16 as a Mouse Model for Human Melanoma. Current Protocols in Immunology, 2000, 39, Unit 20.1.	3.6	298
277	Identification of a CD11b+/Gr-1+/CD31+ myeloid progenitor capable of activating or suppressing CD8+T cells. Blood, 2000, 96, 3838-3846.	0.6	54
278	Autoimmunity and the Immunotherapy of Cancer: Targeting the "Self" to Destroy the "Other". Critical Reviews in Immunology, 2000, 20, 18.	1.0	62
279	Cancer therapy using a self-replicating RNA vaccine. Nature Medicine, 1999, 5, 823-827.	15.2	311
280	Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in anIn vitro melanoma model. , 1999, 80, 781-790.		73
281	DNA and RNA-based vaccines: principles, progress and prospects. Vaccine, 1999, 18, 765-777.	1.7	308
282	Interleukin-10 Enhances the Therapeutic Effectiveness of a Recombinant Poxvirus-Based Vaccine in an Experimental Murine Tumor Model. Journal of Immunotherapy, 1999, 22, 489-496.	1.2	40
283	Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an In vitro melanoma model. , 1999, 80, 781.		1
284	Developing recombinant and synthetic vaccines for the treatment of melanoma. Current Opinion in Oncology, 1999, 11, 50.	1.1	58
285	Transfectant Influenza A Viruses Are Effective Recombinant Immunogens in the Treatment of Experimental Cancer. Virology, 1998, 249, 89-97.	1.1	28
286	Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nature Medicine, 1998, 4, 321-327.	15.2	1,693
287	Generation of polyclonal rabbit antisera to mouse melanoma associated antigens using gene gun immunization. Journal of Immunological Methods, 1998, 214, 51-62.	0.6	14
288	Cancer Vaccines '98: a reductionistic approach. Trends in Molecular Medicine, 1998, 4, 327.	2.6	6

#	Article	IF	Citations
289	T cell-tumor cell: a fatal interaction?. Cancer Immunology, Immunotherapy, 1998, 47, 65-71.	2.0	60
290	Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization. Journal of Experimental Medicine, 1998, 188, 1075-1082.	4.2	539
291	gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of â€œSelfâ€•reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand. Journal of Experimental Medicine, 1998, 188, 277-286.	4.2	437
292	Enhancing Efficacy of Recombinant Anticancer Vaccines With Prime/Boost Regimens That Use Two Different Vectors. Journal of the National Cancer Institute, 1997, 89, 1595-1601.	3.0	145
293	Cloning and Characterization of the Genes Encoding the Murine Homoloties of the Human Melanoma Antigens MARTI and gp100. Journal of Immunotherapy, 1997, 20, 15-16.	1.2	97
294	Dendritic Cells Infected with PoxvIn Vitro iruses Encoding MART-1/ Melan A Sensitize T Lymphocytes In Vitro. Journal of Immunotherapy, 1997, 20, 276-286.	1.2	88
295	Identification of a Kb-restricted CTL Epitope of Î²-Galactosidase: Potential Use in Development of Immunization Protocols for â€œSelfâ€•Antigens. Methods, 1997, 12, 117-123.	1.9	50
296	Highly attenuated modified vaccinia virus Ankara (MVA) as an effective recombinant vector: a Murine tumor model. Vaccine, 1997, 15, 387-394.	1.7	98
297	HLA Associations in the Antitumor Response Against Malignant Melanoma. Journal of Immunotherapy, 1995, 18, 242-252.	1.2	57
298	The next wave of recombinant and synthetic anticancer vaccines. Seminars in Cancer Biology, 1995, 6, 337-347.	4.3	15
299	Molecular Characterization of Defective Antigen Processing in Human Prostate Cancer. Journal of the National Cancer Institute, 1995, 87, 280-285.	3.0	205
300	Anti-Tumor Activity of Cytotoxic T Lymphocytes Elicited with Recombinant and Synthetic Forms of a Model Tumor-Associated Antigen. Journal of Immunotherapy, 1995, 18, 139-146.	1.2	28
301	Recognition of neuroectodermal tumors by melanoma-specific cytotoxic T lymphocytes: evidence for antigen sharing by tumors derived from the neural crest. Cancer Immunology, Immunotherapy, 1994, 39, 73-83.	2.0	23
302	Locus-Specific Analysis of Human Leukocyte Antigen Class I Expression in Melanoma Cell Lines. Journal of Immunotherapy, 1994, 16, 13-23.	1.2	52
303	Retroviral transduction of interferon-? cDNA into a nonimmunogenic murinefibrosarcoma: generation of T cells in draining lymph nodes capable of treating established parental metastatic tumor. Cancer Immunology, Immunotherapy, 1993, 37, 286-292.	2.0	26
304	The multiple uses of viruses for studying antigen processing. Seminars in Virology, 1993, 4, 109-116.	4.1	8
305	Molecular Mechanisms Used by Tumors to Escape Immune Recognition. Journal of Immunotherapy, 1993, 14, 182-190.	1.2	115
306	The effects of euglycemic hyperinsulinemia and amino acid infusion on regional and whole body glucose disposal in man. Metabolism: Clinical and Experimental, 1991, 40, 59-65.	1.5	61

#	Article	IF	Citations
307	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. Cellular and Molecular Immunology, 0, , .	4.8	7
308	Internal Checkpoint Regulates T Cell Neoantigen Reactivity and Susceptibility to PD1 Blockade. SSRN Electronic Journal, 0, , .	0.4	3